Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial by Eron, Joseph J, Prof, Rockstroh, Jürgen K, MD, Reynes, Jacques, Prof, Andrade-Villanueva, Jaime, MD, Ramalho-Madruga, Jose Valdez, MD, Bekker, Linda-Gail, MD, Young, Benjamin, MD, Katlama, Christine, MD, Gatell-Artigas, Jose Maria, MD, Arribas, Jose R, MD, Nelson, Mark, MD, Campbell, Havilland, BS, Zhao, Jing, PhD, Rodgers, Anthony J, MS, Rizk, Matthew L, PhD, Wenning, Larissa, PhD, Miller, Michael D, PhD, Hazuda, Daria, PhD, DiNubile, Mark J, MD, Leavitt, Randi, MD, Isaacs, Robin, MD, Robertson, Michael N, MD, Sklar, Peter, MD, Nguyen, Bach-Yen, Dr

Get full text

Resistance to inhibitors of the human immunodeficiency virus type 1 integration by Hazuda, Daria J.

Get full text